カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の遺伝性検査市場2023-2030：疾患種類別（遺伝性がん検査、遺伝性非がん検査）、技術別（細胞遺伝学、生化学、分子検査）、地域別

【英語タイトル】Hereditary Testing Market Size, Share & Trends Analysis Report By Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), By Technology (Cytogenetic, Biochemical, Molecular Testing), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23JUN054）・商品コード：GRV23JUN054
・発行会社（調査会社）：Grand View Research
・発行日：2023年5月31日
・ページ数：270
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：バイオ
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Grand View Research社の市場調査書によると、世界の遺伝性検査市場規模が、予測期間中に年平均8.4％増加し、2030年までに127.3億ドルへ達すると見込まれています。本調査書では、遺伝性検査の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、疾患種類別（遺伝性がん検査、遺伝性非がん検査）分析、技術別（細胞遺伝学、生化学、分子検査）分析、地域別（北米、ヨーロッパ、アジア太平洋中南米、中東・アフリカ）分析、競争状況などについて調査・分析し、まとめています。なお、こちらに掲載されている企業情報には、Myriad Genetics, Inc.、Invitae Corporation、Illumina, Inc.、Natera, Inc.、Laboratory Corporation of America Holdings、F. Hoffmann-La Roche Ltd.、Quest Diagnostics Incorporated、COOPERSURGICAL, INC.、Agilent Technologies, Inc.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界遺伝性検査の市場規模：疾患種類別
- 遺伝性がん検査の市場規模
- 遺伝性非がん検査の市場規模
・世界遺伝性検査の市場規模：技術別
- 細胞遺伝学的遺伝性検査の市場規模
- 生化学的遺伝性検査の市場規模
- 分子検査の市場規模
・世界遺伝性検査の市場規模：地域別
- 北米の遺伝性検査市場規模
- ヨーロッパの遺伝性検査市場規模
- アジア太平洋の遺伝性検査市場規模
- 中南米の遺伝性検査市場規模
- 中東・アフリカの遺伝性検査市場規模
・競争状況

遺伝性検査市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の遺伝学的検査市場規模は2030年までに127億3000万米ドルに達し、予測期間中のCAGRは8.4%を記録すると予測されています。市場を牽引する主な要因は、シークエンシングのコスト低下と遺伝子検査の低価格化です。さらに、シーケンシング、分析、解釈、集計、市場というゲノミクスのバリューチェーン全体にわたって、ニッチで断片的なポイントソリューションが利用可能であることが、予測期間中の市場成長を促進すると予測されています。

消費者直接遺伝子検査の出現は、個人が自己検査を実施できるようにすることで、遺伝子検査市場に大きな役割を果たすと予想されます。これは遺伝カウンセラーの役割を拡大し、遺伝学的検査の重要性を理解し、適切な検査の選択に役立ちます。登録遺伝カウンセラーの数は増加しており、今後数年間で遺伝性遺伝学的検査の採用を促進するとみられています。

もう一つの重要な市場動向は、生殖遺伝医療分野の拡大です。例えば、Natera社は、女性の健康のための遺伝性疾患遺伝子分析における検査数の一貫した増加を見てきました。これは、遺伝性検査に対する社会的受容の高まりを示すもので、市場拡大に拍車をかけています。新生児スクリーニング機器の取引増加は、DNA実験機器の取引増加に対応しています。また、世界中で新生児スクリーニングが急速に進んでいることも、収益拡大に寄与しています。遺伝性黒色腫を臨床応用に導入するための多遺伝子ボード試験が形成され、これは遺伝子実験基準の変化に促されています。遺伝性健康スコープの拡大は、市場を牽引する最も重要なキーファクターの一つです。

COVID-19のパンデミックは市場に悪影響を与えました。例えば、世界保健機関（WHO）がCOVID-19をパンデミック（世界的大流行）と宣言した後、世界中の政府が予防措置として社会的距離を強制するために封鎖を行いました。どの業界においても、これは激動、制約、挑戦、調整をもたらしました。同様に、今回の感染症発生は遺伝性遺伝子解析分野にも悪影響を及ぼしています。

技術開発者は、診断会社による遺伝子検査の効率を高めるために、先進的な製品を導入しています。例えば、2020年12月、QIAGEN社からQuantiFERON SARS-CoV-2 RUOソリューションが発表されました。QIAGEN社は、分析前サンプルや関連する分子検査ソリューションの技術や製品を提供するビジネスを行っています。このソリューションは、COVID-19を引き起こす感染に対する免疫系のT細胞反応を検出します。このソリューションは、発病と免疫レベルに関する正確な情報を提供します。

遺伝性検査市場レポートハイライト

– 遺伝性がん検査の疾患タイプ別セグメントは、2022年に80.0%を超える収益シェアで市場を独占し、予測期間中に大幅なCAGRで拡大する見込みです。相当数のCLIA認定検査施設が、癌の原因となる遺伝性変異遺伝子を個人が持っているかどうかを判定する検査を実施しています。

– 2021年の遺伝性がん検査市場は、その高い普及率と遺伝性の増加により、乳がん検査分野が支配的でした。子宮頸がんの症例のほとんどは非遺伝性であるため、このセグメントの売上高シェアは最低となりました。

– 遺伝性非がん検査疾患タイプ別セグメントでは、心疾患セグメントがハイスループットシーケンスの出現によって牽引され、その結果、心筋症に対する相当数のシーケンシングアッセイが市販されるようになりました。

– 非侵襲的出生前検査（NIPT）およびがんスクリーニング検査部門と新生児遺伝子スクリーニング部門は、世界中で採用が増加しているため、引き続き有利な成長を示しています。

– さらに、新生児スクリーニングプログラムがいくつかの地域や国で義務化され、遺伝性非がん検査疾患タイプセグメントにおける新生児遺伝子スクリーニングの成長をもたらしています。

– 生殖補助医療の分野と新生児遺伝子スクリーニングの高い普及率により、2022年には欧州が34.8％超の最大収益シェアを占めました。

– 主要企業は新興国での薬事承認取得に取り組み、事業拡大を図っています。相当数の診断企業が技術開発者と提携し、技術ライセンスを取得して顧客に価値の高いサービスを提供しています。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Disease Type
1.1.1.2 Technology
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Insights
2.3 Competitive Insights
Chapter 3 Hereditary Testiing Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Increase in sales and demand for DNA test kits
3.3.1.2 Constantly developing commercial landscape of women’s reproductive health
3.3.1.3 Decline in sequencing cost & consequent expansion of genetic testing registry
3.3.2 Market restraint analysis
3.3.2.1 Ethical and clinical issues of DNA tests
3.3.2.2 Regulatory challenges pertaining to use of DTC genetic tests
3.3.3 Market Opportunity Analysis
3.3.3.1 Increasing incidence of genetic diseases
3.3.3.2 Presence of demand for early and non-invasive fetal testing procedures
3.3.3.3 Introduction of fragmented point-solutions across the genomics value chain
3.4 Hereditary Testing Market Analysis Tools
3.4.1 Industry analysis – Porter’s
3.4.2 PESTLE Analysis
Chapter 4 Hereditary Testing Market – Segment Analysis, By Disease Type, 2018 – 2030 (USD Million)
4.1 Hereditary Testing Market: Disease Type Movement Analysis
4.2 Hereditary Cancer Testing
4.2.1 Hereditary Cancer Testing market estimates and forecast, 2018 – 2030 (USD Million)
4.2.2 Lung cancer
4.2.2.1 Lung cancer market estimates and forecast, 2018 – 2030 (USD Million)
4.2.3 Breast cancer
4.2.3.1 Breast cancer market estimates and forecast, 2018 – 2030 (USD Million)
4.2.4 Colorectal cancer
4.2.4.1 Colorectal cancer market estimates and forecast, 2018 – 2030 (USD Million)
4.2.5 Cervical cancer
4.2.5.1 Cervical cancer market estimates and forecast, 2018 – 2030 (USD Million)
4.2.6 Ovarian cancer
4.2.6.1 Ovarian cancer market estimates and forecast, 2018 – 2030 (USD Million)
4.2.7 Prostate cancer
4.2.7.1 Prostate cancer market estimates and forecast, 2018 – 2030 (USD Million)
4.2.8 Stomach/gastric cancer
4.2.8.1 Stomach/gastric cancer market estimates and forecast, 2018 – 2030 (USD Million)
4.2.9 Melanoma
4.2.9.1 Melanoma market estimates and forecast, 2018 – 2030 (USD Million)
4.2.10 Sarcoma
4.2.10.1 Sarcoma market estimates and forecast, 2018 – 2030 (USD Million)
4.2.11 Uterine cancer
4.2.11.1 Uterine cancer market estimates and forecast, 2018 – 2030 (USD Million)
4.2.12 Pancreatic cancer
4.2.12.1 Pancreatic cancer market estimates and forecast, 2018 – 2030 (USD Million)
4.2.13 Others
4.2.13.1 Others market estimates and forecast, 2018 – 2030 (USD Million)
4.3 Hereditary Non-cancer Testing
4.3.1 Hereditary Non-cancer Testing market estimates and forecast, 2018 – 2030 (USD Million)
4.3.2 Hereditary genetic testing for cardiac disease
4.3.2.1 Hereditary genetic testing for cardiac disease market estimates and forecast, 2018 – 2030 (USD Million)
4.3.3 Hereditary genetic testing for rare disease
4.3.3.1 Hereditary genetic testing for rare disease market estimates and forecast, 2018 – 2030 (USD Million)
4.3.4 Hereditary genetic testing for other diseases
4.3.4.1 Hereditary genetic testing for other diseases market estimates and forecast, 2018 – 2030 (USD Million)
4.3.2 Newborn genetic screening
4.3.2.1 Newborn genetic screening market estimates and forecast, 2018 – 2030 (USD Million)
4.3.3 Preimplantation Genetic Diagnosis & Screening (PGD/PGS)
4.3.3.1 Preimplantation Genetic Diagnosis & Screening (PGD/PGS) market estimates and forecast, 2018 – 2030 (USD Million)
4.3.4 Non-invasive prenatal testing (NIPT) & carrier screening
4.3.4.1 Non-invasive prenatal testing (NIPT) & carrier screening market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 5 Hereditary Testing Market – Segment Analysis, By Technology, 2018 – 2030 (USD Million)
5.1 Hereditary Testing Market: Technology Movement Analysis
5.2 Cytogenetic
5.2.1 Cytogenetic market estimates and forecast, 2018 – 2030 (USD Million)
5.3 Biochemical
5.3.1 Biochemical market estimates and forecast, 2018 – 2030 (USD Million)
5.4 Molecular Testing
5.4.1 Molecular Testing market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 6 Hereditary Testing Market – Segment Analysis, By Region, 2018 – 2030 (USD Million)
6.1 Regional Market Snapshot
6.1.1 North America
6.1.1.1 North America hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.1.2 U.S.
6.1.1.2.1 U.S. hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.1.2.2 Key country dynamics
6.1.1.2.3 Disease prevalence
6.1.1.2.4 Regulatory framework
6.1.1.2.5 Competitive scenario
6.1.1.3 Canada
6.1.1.3.1 Canada hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.1.3.2 Key country dynamics
6.1.1.3.3 Disease prevalence
6.1.1.3.4 Regulatory framework
6.1.1.3.5 Competitive scenario
6.1.2 Europe
6.1.2.1 Europe hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.2.2 UK
6.1.2.2.1 UK hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.2.2.2 Key country dynamics
6.1.2.2.3 Disease prevalence
6.1.2.2.4 Regulatory framework
6.1.2.2.5 Competitive scenario
6.1.2.3 Germany
6.1.2.3.1 Germany hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.2.3.2 Key country dynamics
6.1.2.3.3 Disease prevalence
6.1.2.3.4 Regulatory framework
6.1.2.3.5 Competitive scenario
6.1.2.4 France
6.1.2.4.1 France hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.2.4.2 Key country dynamics
6.1.2.4.3 Disease prevalence
6.1.2.4.4 Regulatory framework
6.1.2.4.5 Competitive scenario
6.1.2.5 Italy
6.1.2.5.1 Italy hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.2.5.2 Key country dynamics
6.1.2.5.3 Disease prevalence
6.1.2.5.4 Regulatory framework
6.1.2.5.5 Competitive scenario
6.1.2.6 Spain
6.1.2.6.1 Spain hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.2.6.2 Key country dynamics
6.1.2.6.3 Disease prevalence
6.1.2.6.4 Regulatory framework
6.1.2.6.5 Competitive scenario
6.1.2.7 Denmark
6.1.2.7.1 Denmark hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.2.7.2 Key country dynamics
6.1.2.7.3 Disease prevalence
6.1.2.7.4 Regulatory framework
6.1.2.7.5 Competitive scenario
6.1.2.8 Sweden
6.1.2.8.1 Sweden hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.2.8.2 Key country dynamics
6.1.2.8.3 Disease prevalence
6.1.2.8.4 Regulatory framework
6.1.2.8.5 Competitive scenario
6.1.2.9 Norway
6.1.2.9.1 Norway hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.2.9.2 Key country dynamics
6.1.2.9.3 Disease prevalence
6.1.2.9.4 Regulatory framework
6.1.2.9.5 Competitive scenario
6.1.3 Asia Pacific
6.1.3.1 Asia Pacific hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.3.2 Japan
6.1.3.2.1 Japan hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.3.2.2 Key country dynamics
6.1.3.2.3 Disease prevalence
6.1.3.2.4 Regulatory framework
6.1.3.2.5 Competitive scenario
6.1.3.3 China
6.1.3.3.1 China hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.3.3.2 Key country dynamics
6.1.3.3.3 Disease prevalence
6.1.3.3.4 Regulatory framework
6.1.3.3.5 Competitive scenario
6.1.3.4 India
6.1.3.4.1 India hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.3.4.2 Key country dynamics
6.1.3.4.3 Disease prevalence
6.1.3.4.4 Regulatory framework
6.1.3.4.5 Competitive scenario
6.1.3.5 South Korea
6.1.3.5.1 South Korea hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.3.5.2 Key country dynamics
6.1.3.5.3 Disease prevalence
6.1.3.5.4 Regulatory framework
6.1.3.5.5 Competitive scenario
6.1.3.6 Australia
6.1.3.6.1 Australia hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.3.6.2 Key country dynamics
6.1.3.6.3 Disease prevalence
6.1.3.6.4 Regulatory framework
6.1.3.6.5 Competitive scenario
6.1.3.7 Thailand
6.1.3.7.1 Thailand hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.3.7.2 Key country dynamics
6.1.3.7.3 Disease prevalence
6.1.3.7.4 Regulatory framework
6.1.3.7.5 Competitive scenario
6.1.4 Latin America
6.1.4.1 Latin America hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.4.2 Brazil
6.1.4.2.1 Brazil hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.4.2.2 Key country dynamics
6.1.4.2.3 Disease prevalence
6.1.4.2.4 Regulatory framework
6.1.4.2.5 Competitive scenario
6.1.4.3 Mexico
6.1.4.3.1 Mexico hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.4.3.2 Key country dynamics
6.1.4.3.3 Disease prevalence
6.1.4.3.4 Regulatory framework
6.1.4.3.5 Competitive scenario
6.1.4.4 Argentina
6.1.4.4.1 Argentina hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.4.4.2 Key country dynamics
6.1.4.4.3 Disease prevalence
6.1.4.4.4 Regulatory framework
6.1.4.4.5 Competitive scenario
6.1.5 MEA
6.1.5.1 MEA hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.5.2 South Africa
6.1.5.2.1 South Africa hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.5.2.2 Key country dynamics
6.1.5.2.3 Disease prevalence
6.1.5.2.4 Regulatory framework
6.1.5.2.5 Competitive scenario
6.1.5.3 Saudi Arabia
6.1.5.3.1 Saudi Arabia hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.5.3.2 Key country dynamics
6.1.5.3.3 Disease prevalence
6.1.5.3.4 Regulatory framework
6.1.5.3.5 Competitive scenario
6.1.5.4 UAE
6.1.5.4.1 UAE hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.5.4.2 Key country dynamics
6.1.5.4.3 Disease prevalence
6.1.5.4.4 Regulatory framework
6.1.5.4.5 Competitive scenario
6.1.5.5 Kuwait
6.1.5.5.1 Kuwait hereditary testing market estimates and forecast, 2018 – 2030 (USD Million)
6.1.5.5.2 Key country dynamics
6.1.5.5.3 Disease prevalence
6.1.5.5.4 Regulatory framework
6.1.5.5.5 Competitive scenario
Chapter 7 Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 New product launch
7.2.2 Partnerships
7.2.3 Acquisition
7.2.4 Collaboration
7.3 Company Market Share Analysis, 2022
7.4 Company Profiles
7.4.1 Myriad Genetics, Inc.
7.4.1.1 Company overview
7.4.1.2 Financial performance
7.4.1.3 Product benchmarking
7.4.1.4 Strategic initiatives
7.4.2 Invitae Corporation
7.4.2.1 Company overview
7.4.2.2 Financial performance
7.4.2.3 Product benchmarking
7.4.2.4 Strategic initiatives
7.4.3 Illumina, Inc.
7.4.3.1 Company overview
7.4.3.2 Financial performance
7.4.3.3 Product benchmarking
7.4.3.4 Strategic initiatives
7.4.4 Natera, Inc.
7.4.4.1 Company overview
7.4.4.2 Financial performance
7.4.4.3 Product benchmarking
7.4.4.4 Strategic initiatives
7.4.5 Laboratory Corporation of America Holdings
7.4.5.1 Company overview
7.4.5.2 Financial performance
7.4.5.3 Product benchmarking
7.4.5.4 Strategic initiatives
7.4.6 F. Hoffmann-La Roche Ltd.
7.4.6.1 Company overview
7.4.6.2 Financial performance
7.4.6.3 Product benchmarking
7.4.6.4 Strategic initiatives
7.4.7 Quest Diagnostics Incorporated
7.4.7.1 Company overview
7.4.7.2 Financial performance
7.4.7.3 Product benchmarking
7.4.7.4 Strategic initiatives
7.4.8 COOPERSURGICAL, INC.
7.4.8.1 Company overview
7.4.8.2 Financial performance
7.4.8.3 Product benchmarking
7.4.8.4 Strategic initiatives
7.4.9 Agilent Technologies, Inc.
7.4.9.1 Company overview
7.4.9.2 Financial performance
7.4.9.3 Product benchmarking
7.4.9.4 Strategic initiatives
7.4.10 Thermo Fisher Scientific, Inc.
7.4.10.1 Company overview
7.4.10.2 Financial performance
7.4.10.3 Product benchmarking
7.4.10.4 Strategic initiatives
7.4.11 Twist Bioscience
7.4.11.1 Company overview
7.4.11.2 Financial performance
7.4.11.3 Product benchmarking
7.4.11.4 Strategic initiatives
7.4.12 SOPHiA GENETICS
7.4.12.1 Company overview
7.4.12.2 Financial performance
7.4.12.3 Product benchmarking
7.4.12.4 Strategic initiatives
7.4.13 Fulgent Genetics
7.4.13.1 Company overview
7.4.13.2 Financial performance
7.4.13.3 Product benchmarking
7.4.13.4 Strategic initiatives
7.4.14 MedGenome
7.4.14.1 Company overview
7.4.14.2 Financial performance
7.4.14.3 Product benchmarking
7.4.14.4 Strategic initiatives
7.4.15 CENTOGENE N.V.
7.4.15.1 Company overview
7.4.15.2 Financial performance
7.4.15.3 Product benchmarking
7.4.15.4 Strategic initiatives

List of Tables

Table 1 Product mapping for hereditary cancer tests
Table 2 DNA sequencing costs over the past decade
Table 3 Global incidence rate of genetic disorders
Table 4 Technology landscape for NIPT tests
Table 5 Comparison of other technologies
Table 6 Countries that prescribe mandatory medical supervision & restriction for genetic tests
Table 7 Susceptibility genes and their prevalence in hereditary ovarian syndromes
Table 8 Various NGS tests for hereditary prostate cancer
Table 9 Genetic testing scenario for patients/families affected by inherited cardiac disease
Table 10 Financial solutions for PGT:
Table 11 Commercial landscape of NIPT for fetal aneuploidy in the U.S.
Table 12 North America hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 13 North America hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 14 North America hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 15 North America hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 16 North America hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 17 U.S. hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 18 U.S. hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 19 U.S. hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 20 U.S. hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 21 U.S. hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 2 2 Canada hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 23 Canada hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 24 Canada hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 25 Canada hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 26 Canada hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 27 Europe hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 28 Europe hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 29 Europe hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 30 Europe hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 31 Europe hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 32 U.K. hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 33 U.K. hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 34 U.K. hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 35 U.K. hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 36 U.K. hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 37 Germany hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 38 Germany hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 39 Germany hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 40 Germany hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 41 Germany hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 42 France hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 43 France hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 44 France hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 45 France hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 46 France hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 47 Spain hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 48 Spain hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 49 Spain hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 50 Spain hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 51 Spain hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 52 Italy hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 53 Italy hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 54 Italy hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 55 Italy hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 56 Italy hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 57 Denmark hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 58 Denmark hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 59 Denmark hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 60 Denmark hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 61 Denmark hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 62 Sweden hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 63 Sweden hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 64 Sweden hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 65 Sweden hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 66 Sweden hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 67 Norway hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 68 Norway hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 69 Norway hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 70 Norway hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 71 Norway hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 72 Asia Pacific hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 73 Asia Pacific hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 74 Asia Pacific hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 75 Asia Pacific hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 76 Asia Pacific hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 77 China hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 78 China hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 79 China hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 80 China hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 81 China hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 82 Japan hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 83 Japan hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 84 Japan hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 85 Japan hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 86 Japan hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 87 India hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 88 India hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 89 India hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 90 India hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 91 India hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 92 South Korea hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 93 South Korea hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 94 South Korea hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 95 South Korea hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 96 South Korea hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 97 Australia hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 98 Australia hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 99 Australia hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 100 Australia hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 101 Australia hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 102 Thailand hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 103 Thailand hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 104 Thailand hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 105 Thailand hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 106 Thailand hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 107 Latin America hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 108 Latin America hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 109 Latin America hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 110 Latin America hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 111 Latin America hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 112 Brazil hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 113 Brazil hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 114 Brazil hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 115 Brazil hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 116 Brazil hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 117 Mexico hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 118 Mexico hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 119 Mexico hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 120 Mexico hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 121 Mexico hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 122 Aergentina hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 123 Aergentina hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 124 Aergentina hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 125 Aergentina hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 126 Aergentina hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 127 MEA hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 128 MEA hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 129 MEA hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 130 MEA hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 131 MEA hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 132 South Africa hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 133 South Africa hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 134 South Africa hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 135 South Africa hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 136 South Africa hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 137 Saudi Arabia hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 138 Saudi Arabia hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 139 Saudi Arabia hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 140 Saudi Arabia hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 141 Saudi Arabia hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 142 UAE hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 143 UAE hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 144 UAE hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 145 UAE hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 146 UAE hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 147 Kuwait hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 148 Kuwait hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 149 Kuwait hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 150 Kuwait hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 151 Kuwait hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)

★調査レポート[世界の遺伝性検査市場2023-2030：疾患種類別（遺伝性がん検査、遺伝性非がん検査）、技術別（細胞遺伝学、生化学、分子検査）、地域別] (コード：GRV23JUN054)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の遺伝性検査市場2023-2030：疾患種類別（遺伝性がん検査、遺伝性非がん検査）、技術別（細胞遺伝学、生化学、分子検査）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の難聴疾患治療市場2023-2030：製品別（機器、医薬品）、疾患種類別（伝導性難聴、感音性難聴）、エンドユーザー別（病院、耳鼻科診療所）
  • 世界のデュピュイトラン病市場2023-2030：種類別（診断、治療）、疾患種類別（タイプ I、タイプ II）、最終用途別（病院、診療所）、地域別（ヨーロッパ、アジア太平洋）
  • 世界の緑内障市場2023-2030：疾患種類別（開放隅角緑内障、閉塞隅角緑内障）、薬剤クラス別（プロスタグランジン類縁体、ベータ遮断薬）、流通チャネル別、地域別
  • 世界のがんワクチン市場2023-2030：疾患種類別（膀胱、子宮頸部）、ワクチン種類別（予防、治療）、技術種類別（組換え、全細胞）、地域別
  • 世界の網膜静脈閉塞症治療市場（2023-2030）：エンドユーザー別（小売薬局、病院・診療所）、疾患種類別（CRVO、BRVO）、治療薬別（抗VEGF薬、副腎皮質ステロイド薬）、地域別
  • 世界の肺がん診断市場2023-2030：がん種類別（小細胞肺がん、非小細胞肺がん）、検査別（画像検査、生検、喀痰細胞診、分子検査）、エンドユーザー別（病院、専門クリニック、その他）、地域別
  • 世界の腸疾患検査市場2023-2030：疾患種類別（細菌性腸疾患、ウイルス性腸疾患、寄生性腸疾患）、地域別
  • 世界の結核治療薬市場2023-2030：疾患種類別（活動性結核、潜在性結核）、治療法別、投与経路別、剤形別、流通チャネル別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆